These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39354562)

  • 21. Combining the radiomic features and traditional parameters of
    Chen YH; Lue KH; Chu SC; Chang BS; Wang LY; Liu DW; Liu SH; Chao YK; Chan SC
    Ann Nucl Med; 2019 Sep; 33(9):657-670. PubMed ID: 31218571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Computerized Tomography (PET-CT) Scan in Identifying Interval Metastases for Patients with Esophageal Cancer.
    Gabriel E; Alnaji R; Du W; Attwood K; Kukar M; Hochwald S
    Ann Surg Oncol; 2017 Jun; 24(6):1739-1746. PubMed ID: 28058562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detecting Interval Distant Metastases With 18F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer.
    Kroese TE; Ruurda JP; Bakker AS; Jairam J; Mook S; van der Horst S; Meijer GJ; Haj Mohammad N; van Rossum PSN; van Hillegersberg R
    Clin Nucl Med; 2022 Jun; 47(6):496-502. PubMed ID: 35384907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
    Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
    Molena D; Sun HH; Badr AS; Mungo B; Sarkaria IS; Adusumilli PS; Bains MS; Rusch VW; Ilson DH; Rizk NP
    Dis Esophagus; 2014; 27(4):355-9. PubMed ID: 24033404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
    Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
    Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
    Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma.
    Makino T; Doki Y; Miyata H; Yasuda T; Yamasaki M; Fujiwara Y; Takiguchi S; Higuchi I; Hatazawa J; Monden M
    Surgery; 2008 Nov; 144(5):793-802. PubMed ID: 19081023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
    Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Ohsawa M; Hirohata R; Kitasaki N; Okada M
    Anticancer Res; 2022 Dec; 42(12):6037-6045. PubMed ID: 36456150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of the primary tumor's SUVmax with survival after surgery for clinical stage IA esophageal cancer: a single-center retrospective study.
    Miyawaki Y; Sato H; Fujiwara N; Oya S; Sugita H; Hirano Y; Yamane T; Sakuramoto S; Okamoto K; Yamaguchi S; Koyama I
    Int J Clin Oncol; 2020 Apr; 25(4):561-569. PubMed ID: 31867680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus.
    Dewan A; Sharma SK; Dewan AK; Khurana R; Gupta M; Pahuja A; Srivastava H; Sinha R
    J Gastrointest Cancer; 2017 Mar; 48(1):42-49. PubMed ID: 27604122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Kemuriyama K; Sasaki Y; Imai K; Maeda E; Minamiya Y
    Ann Surg Oncol; 2022 Feb; 29(2):1336-1346. PubMed ID: 34355333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy.
    Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Kitasaki N; Okada M
    Surgery; 2022 Aug; 172(2):584-592. PubMed ID: 35523595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of treatment response assessed by 18F-FDG PET/CT with the histopathological response using tumor regression grading on surgically resected specimen following neoadjuvant chemotherapy in squamous cell carcinoma of esophagus.
    Kumar N; Deo S; Bhoriwal S; Sharma A; Pramanik R; Kumar R; Das P; Arora S; Kumar S
    Nucl Med Commun; 2021 Aug; 42(8):928-934. PubMed ID: 33795613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma.
    Elliott JA; O'Farrell NJ; King S; Halpenny D; Malik V; Muldoon C; Johnston C; Reynolds JV
    Br J Surg; 2014 Dec; 101(13):1702-11. PubMed ID: 25351460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy.
    Manoharan V; Lee S; Chong S; Yap J; Coupe N; Wilson R; Merrett N; Ng W; Lin M
    Ann Nucl Med; 2017 May; 31(4):315-323. PubMed ID: 28299585
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Mantziari S; Pomoni A; Prior JO; Winiker M; Allemann P; Demartines N; Schäfer M
    BMC Med Imaging; 2020 Jan; 20(1):7. PubMed ID: 31969127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
    Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
    J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.